IL307992B2 - Isoxazoline parasiticide formulations and methodsfor treating blepharitis - Google Patents

Isoxazoline parasiticide formulations and methodsfor treating blepharitis

Info

Publication number
IL307992B2
IL307992B2 IL307992A IL30799223A IL307992B2 IL 307992 B2 IL307992 B2 IL 307992B2 IL 307992 A IL307992 A IL 307992A IL 30799223 A IL30799223 A IL 30799223A IL 307992 B2 IL307992 B2 IL 307992B2
Authority
IL
Israel
Prior art keywords
composition
use according
patient
isoxazoline parasiticide
delivered
Prior art date
Application number
IL307992A
Other languages
Hebrew (he)
Other versions
IL307992A (en
IL307992B1 (en
Inventor
Shawn D Hickok
Bobak Robert Azamian
Joseph G Vehige
Douglas Michael Ackermann
Original Assignee
Tarsus Pharmaceuticals Inc
Shawn D Hickok
Bobak Robert Azamian
Joseph G Vehige
Douglas Michael Ackermann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66814591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL307992(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tarsus Pharmaceuticals Inc, Shawn D Hickok, Bobak Robert Azamian, Joseph G Vehige, Douglas Michael Ackermann filed Critical Tarsus Pharmaceuticals Inc
Publication of IL307992A publication Critical patent/IL307992A/en
Publication of IL307992B1 publication Critical patent/IL307992B1/en
Publication of IL307992B2 publication Critical patent/IL307992B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (53)

1. 307992/ -42- Claims 1. An ophthalmic composition for use in reducing eyelid collarettes in a human patient, wherein the composition comprises an effective amount of an isoxazoline parasiticide and a pharmaceutically acceptable vehicle, and wherein the composition is topically delivered to one or more of the eyes, eyelids, or eyelashes of the patient.
2. The composition for use according to Claim 1, wherein the ophthalmic composition comprises an eye drop.
3. The composition for use according to Claim 1 or 2, wherein the composition does not include any essential oils.
4. The composition for use according to any one of the preceding claims, wherein the isoxazoline parasiticide is selected from the group consisting of: fluralaner, sarolaner, lotilaner, afoxolaner and fluxametamide.
5. The composition for use according to Claim 4, wherein the isoxazoline parasiticide comprises lotilaner.
6. The composition for use according to any one of the preceding claims, wherein the isoxazoline parasiticide is the sole active ingredient of the composition.
7. The composition for use according to any one of the preceding claims, wherein the composition comprises a castor oil, but not a polysorbate.
8. An ophthalmic composition for use in reducing eyelid collarettes in a human patient, wherein the composition comprises an effective amount of an isoxazoline parasiticide, a pharmaceutically acceptable vehicle, and a castor oil, wherein the isoxazoline parasiticide is the sole active ingredient of the composition, and wherein the composition is topically delivered to one or more of the eyes, eyelids, or eyelashes of the patient. -43-
9. The composition for use according to Claim 8, wherein the patient’s eyes are closed upon topically administering the composition, such that the composition contacts orifices of Meibomian glands of the patient and outside of eyelid margins of the patient.
10. The composition for use according to Claim 9, wherein the composition is intended to be spread onto the eyelashes and follicles of the eyelashes.
11. The composition for use according to Claim 10, wherein the composition is intended to be spread onto the eyelashes and follicles of the eyelashes with an applicator.
12. The composition for use according to any one of Claims 8 to 11, wherein the composition comprises from 0.001% to 1% of the isoxazoline parasiticide.
13. The composition for use according to any one of Claims 8 to 12, wherein the composition is intended to be administered at least once daily for at least 2 weeks.
14. The composition for use according to Claim 13, wherein the composition is intended to be administered at least once daily for at least 4 weeks.
15. The composition for use according to any one of Claims 8 to 14, wherein the isoxazoline parasiticide comprises lotilaner.
16. An ophthalmic composition for use in reducing eyelid collarettes in a human patient, wherein the composition comprises an effective amount of an isoxazoline parasiticide and a pharmaceutically acceptable vehicle, wherein the isoxazoline parasiticide is the sole active ingredient of the composition, wherein the composition is topically delivered to one or more of the eyes, eyelids, or eyelashes of the patient, and wherein the volume of the composition delivered is less than 100 microliters.
17. The composition for use according to Claim 16, wherein the composition is intended to be administered following a first assessment of a quantity of Demodex mites on an anatomical structure of the patient indicating the quantity of Demodex mites is greater than a predetermined value.
18. The composition for use according to Claim 17, wherein the predetermined value is 1 mite per lash. -44-
19. The composition for use according to Claim 16, wherein the composition is intended to be administered following a first assessment of a quantity of collarettes on an anatomical structure of the patient indicating the quantity of collarettes is greater than a predetermined value.
20. The composition for use according to Claim 19, wherein the predetermined value is 3 collarettes.
21. The composition for use according to Claim 19, wherein the predetermined value is 10 collarettes.
22. The composition for use according to any one of Claims 16 to 21, wherein the isoxazoline parasiticide comprises lotilaner.
23. A topical composition for use in treating an ocular Demodex infestation in a human patient, wherein the composition comprises an effective amount of an isoxazoline parasiticide and a pharmaceutically acceptable vehicle, and wherein the composition is formulated as a gel, an ointment, or a cream.
24. The composition for use according to Claim 23, wherein the composition is topically delivered to one or more of the eyes, eyelids, or eyelashes of the patient.
25. The composition for use according to Claim 23 or 24, wherein from 0.01% to 1% of the isoxazoline parasiticide with respect to the total weight of the composition is delivered to the patient.
26. The composition for use according to Claim 25, wherein from 0.15% to 0.40% of the isoxazoline parasiticide with respect to the total weight of the composition is delivered to the patient.
27. The composition for use according to Claim 26, wherein 0.25% of the isoxazoline parasiticide with respect to the total weight of the composition is delivered to the patient.
28. The composition for use according to any one any one of Claims 23 to 27, wherein the isoxazoline parasiticide is selected from the group consisting of: fluralaner, sarolaner, lotilaner, afoxolaner and fluxametamide.
29. The composition for use according to Claim 28, wherein the isoxazoline parasiticide comprises lotilaner. -45-
30. The composition for use according to any one of Claims 23 to 29, wherein the composition does not include any essential oils.
31. The composition for use according to any one of Claims 23 to 30, wherein the composition does not include tea tree oil.
32. The composition for use according to any one of Claims 23 to 31, wherein the isoxazoline parasiticide is the sole active ingredient of the composition.
33. The composition for use according to any one of Claims 23 to 32, wherein the composition is topically administered at least once daily for at least 2 weeks.
34. The composition for use according to Claim 33, wherein the composition is topically administered at least once daily for at least 4 weeks.
35. The composition for use according to Claim 34, wherein the composition is topically administered at least once daily for at least 6 weeks.
36. The composition for use according to any Claim 33, wherein the composition is topically administered at least twice daily for at least 2 weeks.
37. The composition for use according to any one of Claims 23 to 36, wherein the composition comprises a castor oil.
38. The composition for use according to Claim 37, wherein the castor oil comprises hydrogenated castor oil.
39. A dermatological composition for use in treating rosacea in a human patient, wherein the composition comprises an effective amount of an isoxazoline parasiticide and a pharmaceutically acceptable vehicle, and wherein the composition is formulated as a gel, an ointment, or a cream.
40. The composition for use according to Claim 39, wherein the composition is topically delivered to one or more of the eyes, eyelids, or eyelashes of the patient.
41. The composition for use according to Claim 39 or 40, wherein from 0.001% to 10% of the isoxazoline parasiticide with respect to the total weight of the composition is delivered to the patient.
42. The composition for use according to Claim 41, wherein from 0.1% to 10% of the isoxazoline parasiticide with respect to the total weight of the composition is delivered to the patient. -46-
43. The composition for use according to Claim 41, wherein from 0.01% to 5% of the isoxazoline parasiticide with respect to the total weight of the composition is delivered to the patient.
44. The composition for use according to Claim 43, wherein 2% of the isoxazoline parasiticide with respect to the total weight of the composition is delivered to the patient.
45. The composition for use according to Claim 43, wherein 1% of the isoxazoline parasiticide with respect to the total weight of the composition is delivered to the patient.
46. The composition for use according to any one any one of Claims 39 to 45, wherein the isoxazoline parasiticide is selected from the group consisting of: fluralaner, sarolaner, lotilaner, afoxolaner and fluxametamide.
47. The composition for use according to Claim 46, wherein the isoxazoline parasiticide comprises lotilaner.
48. The composition for use according to any one of Claims 39 to 47, wherein the composition does not include any essential oils.
49. The composition for use according to any one of Claims 39 to 48, wherein the isoxazoline parasiticide is the sole active ingredient of the composition.
50. The composition for use according to any one of Claims 39 to 49, wherein the composition is topically administered at least once daily for at least 2 weeks.
51. The composition for use according to Claim 50, wherein the composition is topically administered at least once daily for at least 4 weeks.
52. The composition for use according to Claim 51, wherein the composition is topically administered at least once daily for at least 6 weeks.
53. The composition for use according to Claim 50, wherein the composition is topically administered at least twice daily for at least 2 weeks.
IL307992A 2017-12-15 2018-12-14 Isoxazoline parasiticide formulations and methodsfor treating blepharitis IL307992B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762599213P 2017-12-15 2017-12-15
US201862615855P 2018-01-10 2018-01-10
US201862626612P 2018-02-05 2018-02-05
US201862689787P 2018-06-25 2018-06-25
US201862746498P 2018-10-16 2018-10-16
PCT/US2018/065849 WO2019118928A1 (en) 2017-12-15 2018-12-14 Isoxazoline parasiticide formulations and methods for treating blepharitis

Publications (3)

Publication Number Publication Date
IL307992A IL307992A (en) 2023-12-01
IL307992B1 IL307992B1 (en) 2024-11-01
IL307992B2 true IL307992B2 (en) 2025-03-01

Family

ID=66814591

Family Applications (3)

Application Number Title Priority Date Filing Date
IL316352A IL316352A (en) 2017-12-15 2018-12-14 Isoxazoline parasiticide formulations and methodsfor treating blepharitis
IL307992A IL307992B2 (en) 2017-12-15 2018-12-14 Isoxazoline parasiticide formulations and methodsfor treating blepharitis
IL275339A IL275339B2 (en) 2017-12-15 2018-12-14 Parasitic formulations containing isoxazoline and methods for treating blepharitis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL316352A IL316352A (en) 2017-12-15 2018-12-14 Isoxazoline parasiticide formulations and methodsfor treating blepharitis

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL275339A IL275339B2 (en) 2017-12-15 2018-12-14 Parasitic formulations containing isoxazoline and methods for treating blepharitis

Country Status (19)

Country Link
US (14) US10835517B2 (en)
EP (2) EP3723739B1 (en)
JP (2) JP2021506971A (en)
KR (4) KR20200111177A (en)
CN (3) CN119174758A (en)
AU (3) AU2018385766B2 (en)
BR (1) BR112020012018A2 (en)
CA (1) CA3085787A1 (en)
DK (1) DK3723739T3 (en)
ES (1) ES2981130T3 (en)
FI (1) FI3723739T3 (en)
HU (1) HUE067461T2 (en)
IL (3) IL316352A (en)
MX (2) MX2020006309A (en)
PL (1) PL3723739T3 (en)
PT (1) PT3723739T (en)
SI (1) SI3723739T1 (en)
WO (1) WO2019118928A1 (en)
ZA (1) ZA202004155B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
PT3723739T (en) 2017-12-15 2024-06-21 Tarsus Pharmaceuticals Inc ISOXAZOLINE PARASITICIDE FORMULATIONS AND THEIR USE FOR THE TREATMENT OF BLEPHARITIS
WO2020023943A1 (en) 2018-07-27 2020-01-30 Aperta Biosciences, Llc Spinosyn formulations for treatment of demodex-induced ocular and facial conditions
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
EP3986377A4 (en) * 2019-06-19 2023-07-19 Tarsus Pharmaceuticals, Inc. ISOXAZOLINE PARASITICIDAL FORMULATIONS AND METHODS OF TREATING BLEPHARITIS
CA3249527A1 (en) * 2022-04-22 2023-10-26 Attillaps Holdings Inc. Anticholinergic agents and muscarinic agonists for the treatment of demodex related conditions
WO2024168149A1 (en) * 2023-02-10 2024-08-15 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
KR20250143845A (en) * 2023-04-08 2025-10-02 성-잔 린 Treatment of corneal damage
AU2024322403A1 (en) * 2023-08-04 2026-02-12 Ads Therapeutics Llc Compositions and methods for delivery of ophthalmological actives

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2361974A (en) 1940-02-07 1944-11-07 John A Rietmann Electrolytic cell
US3781355A (en) 1969-12-12 1973-12-25 Boots Pure Drug Co Ltd Pesticidal compounds and compositions
US3864497A (en) 1970-12-01 1975-02-04 Boots Pure Drug Co Ltd Acaricidal and insecticidal 1,5-diphenyl-3-methyl-1,3,5-triazapenta-1,4-diener
JPS6033429Y2 (en) 1975-09-30 1985-10-04 株式会社田村電機製作所 Frequency switching mechanism
US4389397A (en) 1980-08-04 1983-06-21 Merck & Co., Inc. Solubilization of ivermectin in water
US5019392A (en) 1988-03-03 1991-05-28 Micro-Pak, Inc. Encapsulation of parasiticides
US4957918A (en) 1988-06-09 1990-09-18 Leonard Bloom Topical treatment of blepharitis
US5614545A (en) 1988-06-09 1997-03-25 Leonard Bloom Topical composition for treatment of blepharitis
US6001822A (en) 1989-04-11 1999-12-14 Pfizer Inc. Antiparasitic formulations
FR2656526B1 (en) 1990-01-02 1994-10-28 Virbac Sa Laboratoires CONTROLLED RELEASE DEVICE AND PREPARATION METHOD.
WO1994015597A1 (en) * 1993-01-11 1994-07-21 Allergan, Inc. Ophthalmic compositions comprising benzyllauryldimethylammonium chloride
US5632999A (en) 1993-08-18 1997-05-27 Virbac, Inc. Sustained release pyriproxifen compositions for parasite control
US5981500A (en) 1994-01-12 1999-11-09 Pfizer Inc. Antiparasitic agents related to the milbemycins and avermectins
FR2729539B1 (en) 1995-01-23 1997-04-11 Virbac Lab DEVICE FOR CONTROLLED RELEASE OF CHEMICAL SUBSTANCES, FOR FIXING ON AN ANIMAL AND METHOD FOR PREPARING SAID DEVICE
DE19613972A1 (en) 1996-04-09 1997-10-16 Bayer Ag Injection formulations of avermectins and milbemycins based on castor oil
RU2126668C1 (en) 1996-10-17 1999-02-27 Багров Сергей Николаевич Ointment demalon for treatment of patients with blepharitis
FR2761886B1 (en) 1997-04-14 2000-05-05 Virbac Sa COMPOSITIONS CONTAINING AT LEAST ONE CATIONIC POLYMER AND AT LEAST ONE ACTIVE MOLECULE CONTAINED IN AT LEAST ONE MICRO OR NANOPARTICLE VECTOR AND THEIR USE FOR THE TREATMENT OF LIVE OR INERT SURFACES
US5968990A (en) 1997-10-14 1999-10-19 Isp Investments Inc. Water-dilutable, microemulsion concentrate and pour-on formulations thereof
US6255350B1 (en) 1997-10-14 2001-07-03 Isp Investments Inc. Stabilized concentrates of water unstable AZA compounds and o/w miniemulsions thereof
US6455583B1 (en) 1998-05-08 2002-09-24 The University Of Miami Method for treating meibomian gland disease
US5952372A (en) 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
GB9825402D0 (en) 1998-11-19 1999-01-13 Pfizer Ltd Antiparasitic formulations
US7897559B2 (en) 2000-06-29 2011-03-01 Parks L Dean Dermatological composition and kit containing avermectin compound for treating dermatological conditions
US6696067B2 (en) 2001-04-12 2004-02-24 Ondeo Nalco Company Cosmetic compositions containing dispersion polymers
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
IL147921A0 (en) 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
EP1476121A4 (en) 2002-02-08 2010-10-27 Merck Sharp & Dohme TOPICAL COMPOSITION OF IVERMECTIN
US7906128B2 (en) 2002-10-21 2011-03-15 Wyeth Llc Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals
EP1620113B1 (en) 2003-04-24 2011-07-13 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
FR2854074B1 (en) 2003-04-24 2007-11-23 Galderma Res & Dev USE OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS
US7531186B2 (en) 2003-12-17 2009-05-12 Merial Limited Topical formulations comprising 1-N-arylpyrazole derivatives and amitraz
CN102558082B (en) 2004-03-05 2015-09-30 日产化学工业株式会社 Isoxazoline-substituted benzamide compound prepare intermediate
EP1758576A1 (en) 2004-03-12 2007-03-07 Christian Diehl Topical and intravaginal microbicidal and antiparasitic compositions comprising quassinoids or quassionid-containing plant extracts
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
TWI350728B (en) 2004-10-08 2011-10-21 Wyeth Corp Amitraz compositions
GB2419093A (en) 2004-10-12 2006-04-19 Ernir Snorrason Acetylcholinesterase inhibitors for the treatment of skin
EP1807087A2 (en) 2004-10-12 2007-07-18 Ernir Snorrason Inhibitors of acetylcholinesterase for treating skin diseases
WO2006050837A2 (en) 2004-11-09 2006-05-18 Novagali Pharma Sa Ophthalmic emulsions containing an immunosuppressive agent
DE102004053964A1 (en) 2004-11-09 2006-05-11 Bayer Healthcare Ag Remedy for demodicosis
WO2006119174A1 (en) 2005-04-30 2006-11-09 Ocular Surface Center, P.A. Method for treating ocular demodex
FR2886851B1 (en) 2005-06-10 2007-10-05 Galderma Sa COMPOSITION BASED ON AVERMECTIN AND METRONIDAZOLE, IN PARTICULAR FOR THE TREATMENT OF ROSACEA
CA2621228C (en) 2005-09-02 2014-05-27 Nissan Chemical Industries, Ltd. Isoxazoline-substituted benzamide compound and pesticide
FR2891460B1 (en) 2005-09-30 2010-07-30 Galderma Sa USE OF AT LEAST ONE COMPOUND OF THE AVERMECTIN FAMILY FOR THE TREATMENT OF OPHTHALMIC DISEASES DUE TO DEMODEX FOLLICULORUM.
JP2009519937A (en) 2005-12-14 2009-05-21 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Isoxazolines for invertebrate pest control
TW200803740A (en) 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
TWI412322B (en) 2005-12-30 2013-10-21 Du Pont Isoxazolines for controlling invertebrate pests
FR2900052B1 (en) 2006-04-19 2011-02-18 Galderma Sa COMPOSITION COMPRISING AT LEAST ONE AQUEOUS PHASE AND AT LEAST ONE FATTY PHASE COMPRISING IVERMECTIN
BRPI0710403A2 (en) 2006-04-20 2011-08-09 Du Pont compound composition, control composition, spraying, bait, trap device, control methods, protection methods, treated seed, protective composition
JP2008044880A (en) 2006-08-15 2008-02-28 Bayer Cropscience Ag Insecticidal isooxazolines
JP5256753B2 (en) 2007-03-29 2013-08-07 住友化学株式会社 Isoxazoline compounds and their pest control applications
CA2683180A1 (en) 2007-04-10 2008-10-16 Bayer Cropscience Ag Insecticidal aryl isoxazoline derivatives
WO2008138516A1 (en) * 2007-05-09 2008-11-20 Ganial Immunoterapeutics Inc. (s,r)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent
MX2009013469A (en) 2007-06-13 2010-01-20 Du Pont Isoxazoline insecticides.
TWI556741B (en) 2007-08-17 2016-11-11 英特威特國際股份有限公司 Isoxazoline compositions and their use as antiparasitics
US8128968B2 (en) 2007-08-29 2012-03-06 Tissuetech, Inc. Compositions and methods for treating Demodex infestations
KR20100075996A (en) 2007-10-03 2010-07-05 이 아이 듀폰 디 네모아 앤드 캄파니 Naphthalene isoxazoline compounds for control of invertebrate pests
FR2922108A1 (en) 2007-10-11 2009-04-17 Virbac Sa USE OF A 1-N- (HALO-3-PYRIDYLMETHYL) -N-METHYLAMINO-1-ALKYLAMINO -2-NITROETHYLENE DERIVATIVE FOR THE PREPARATION OF A VETERINARY PHARMACEUTICAL COMPOSITION FOR CONTROLLING CHIPS
FR2925337B1 (en) 2007-12-21 2010-01-15 Virbac PHARMACEUTICAL COMPOSITION CONTAINING AN N-PHENYLPYRAZOLE DERIVATIVE AND GLYCOFUROL, USE FOR THE PREPARATION OF A TOPICAL VETERINARY DRUG FOR CONTROLLING CHIPS
CA2719453A1 (en) 2008-03-26 2009-10-01 Eric Donnenfeld Methods for improving lid margin and tear film function and treatment of lid margin disease using tetracycline family antibiotics
US20090317503A1 (en) 2008-06-20 2009-12-24 Ocusoft, Inc. Eyelid Preparation and Method of Use
EP2308857B1 (en) 2008-07-09 2016-04-27 Nissan Chemical Industries, Ltd. Process for production of isoxazoline-substituted benzoic acid amide compound
EP2306837B2 (en) 2008-07-09 2023-10-25 Basf Se Pesticidal active mixtures comprising isoxazoline compounds i
ES2781828T3 (en) 2008-11-19 2020-09-08 Boehringer Ingelheim Animal Health Usa Inc Compositions comprising an aryl pyrazole and / or a formamidine, methods and uses thereof
US9173728B2 (en) 2008-11-19 2015-11-03 Merial Inc. Multi-cavity container having offset indentures for dispensing fluids
EP2375905B1 (en) 2008-12-16 2012-12-05 Virbac Pharmaceutical composition containing an n-phenylpyrazole derivative, and use thereof for preparing a topical veterinary drug for flea control
EP2379537B9 (en) 2008-12-19 2017-07-12 Novartis AG Isoxazoline derivatives and their use as pesticide
US8313752B2 (en) 2009-04-14 2012-11-20 Merial Limited Macrocyclic lactone combination compositions, vaccines and methods for producing same
FR2945797B1 (en) 2009-05-20 2015-11-06 Virbac Sa FOOD, PHARMACEUTICAL OR VETERINARY SAFETY PACKAGING AND METHOD OF MANUFACTURING THE SAME
JP5246182B2 (en) 2010-02-24 2013-07-24 ライオン株式会社 Eye drops, preservatives and preservatives
EP2542246A1 (en) 2010-03-03 2013-01-09 Neocutis SA Compositions and methods for treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
GB2480899B (en) 2010-04-12 2014-11-19 Exosect Ltd Control of arthropods in animal environments
US8211450B2 (en) 2010-05-05 2012-07-03 Senju Usa, Inc. Ophthalmic composition
CN102260252A (en) * 2010-05-24 2011-11-30 盟科医药技术(上海)有限公司 Novel oxazolidinone used for treating bacterial infection
RU2472505C2 (en) 2010-12-07 2013-01-20 Общество с ограниченной ответственностью "Экохимтех" Therapeutic antimalaria drug based on antimalaria agent and probiotic
US20160184340A1 (en) * 2010-12-22 2016-06-30 Christine Kritikou The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents
BR112013015503A2 (en) 2010-12-27 2017-06-27 Intervet Int Bv topical localized formulation, use of a formulation, and method for treating or prophylaxing an animal's parasite infestation
JP5952302B2 (en) 2010-12-29 2016-07-13 ニチャミン、ルイス・ディー Methods and kits for eye treatment
AR085354A1 (en) 2011-02-10 2013-09-25 Novartis Ag ISOXAZOL DERIVATIVES FOR CONTROL OF INVESTED PESTS
HRP20160601T1 (en) 2011-03-10 2016-07-01 Zoetis Services Llc Spirocyclic isoxazoline derivatives as antiparasitic agents
CN103687594A (en) * 2011-04-05 2014-03-26 奥普托索夫有限公司 Ophthalmic treatment
MY198581A (en) * 2011-09-12 2023-09-06 Boehringer Ingelheim Animal Health Usa Inc Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof
CN102552114A (en) 2012-03-19 2012-07-11 段亚东 Metronidazole ophthalmic gel and preparation method and application thereof
US9345522B2 (en) 2012-05-22 2016-05-24 Matthew Songer Bone fixation screw and method
HRP20180861T1 (en) 2012-08-31 2018-07-13 Zoetis Services Llc Crystalline forms of 1-(5'-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'h-spiro[azetidine-3,1'-isobenzofuran]-1-yl)-2-(methylsulfonyl)ethanone
US9095566B1 (en) 2013-06-28 2015-08-04 Edward Quicksilver Yavitz Eyelash and eyelid margin infections
US9233117B2 (en) 2013-07-08 2016-01-12 Galderma S. A. Treatment of inflammatory lesions of rosacea with ivermectin
WO2015017328A2 (en) 2013-07-29 2015-02-05 Spallitta Frank Anthony Organophosphates for treating afflictions of the skin
WO2019126541A1 (en) 2017-12-20 2019-06-27 Attillaps Holdings Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
PL4306168T3 (en) * 2013-12-20 2025-11-17 Intervet International B.V. Isoxazoline compositions and use thereof in the prevention or treatment of parasite infestations in animals
WO2015183799A1 (en) 2014-05-28 2015-12-03 Macular Health, Llc Ocular eyelid scrub composition for the treatment of demodex blepharitis
LT3157534T (en) 2014-06-19 2022-09-12 Attillaps Holdings Acetylcholinesterase inhibitors for treatment of dermatological conditions
TW201625564A (en) 2014-07-23 2016-07-16 陶氏農業科學公司 Molecules with certain insecticidal effects and related intermediates, compositions and methods (2)
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
WO2016073347A1 (en) * 2014-11-03 2016-05-12 Zoetis Services Llc Palatable chewable veterinary composition
US20170348286A1 (en) * 2014-12-22 2017-12-07 Intervet Inc. Use of isoxazoline compounds for treating demodicosis
CA2976120A1 (en) * 2015-02-24 2016-09-01 The Board Of Trustees Of The University Of Illinois Use of brimonidine for treating dry eye syndrome
UY36570A (en) 2015-02-26 2016-10-31 Merial Inc INJECTABLE FORMULATIONS OF PROLONGED ACTION THAT INCLUDE AN ISOXAZOLINE ACTIVE AGENT, METHODS AND USES OF THE SAME
US20160287566A1 (en) 2015-04-04 2016-10-06 Thomas Lynn Busby Anti-demodectic active agents and topical compositions for the treatment of demodicosis in humans and animals
HUE059228T2 (en) * 2015-06-23 2022-10-28 Intervet Int Bv Isoxazoline solution containing vitamin E, for use with disinfected drinking water
US20170024748A1 (en) 2015-07-22 2017-01-26 Patient Doctor Technologies, Inc. Guided discussion platform for multiple parties
AU2016317848A1 (en) * 2015-09-03 2018-03-15 Agrimetis, Llc Spinosyn derivatives as insecticides
NZ739853A (en) 2015-09-10 2018-11-30 Dow Agrosciences Llc Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
CN113144203B (en) 2015-09-28 2025-01-28 阿祖拉眼科有限公司 Thiol- and disulfide-containing agents for increasing lipid secretion from the meibomian glands
UY37137A (en) 2016-02-24 2017-09-29 Merial Inc ANTIPARASITARY COMPOUNDS OF ISOXAZOLINE, INJECTABLE FORMULATIONS OF PROLONGED ACTION THAT INCLUDE THEM, METHODS AND USES OF THE SAME
CN114805234A (en) 2016-04-06 2022-07-29 勃林格殷格翰动物保健美国公司 Process for the preparation of crystalline toluene solvates of enantiomerically enriched isoxazoline compounds-(S)-afoxolaner
JP2019513799A (en) 2016-04-12 2019-05-30 イラストリス ファーマシューティカルズ、インク． Compositions for the topical application of compounds
JP7051703B2 (en) 2016-04-15 2022-04-11 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Pyrazolopyrimidine derivative
MX2019005040A (en) 2016-10-31 2019-10-30 Tropiq Health Sciences Methods and compositions for preventing vector-borne disease transmission.
PT3723739T (en) 2017-12-15 2024-06-21 Tarsus Pharmaceuticals Inc ISOXAZOLINE PARASITICIDE FORMULATIONS AND THEIR USE FOR THE TREATMENT OF BLEPHARITIS
WO2020023943A1 (en) 2018-07-27 2020-01-30 Aperta Biosciences, Llc Spinosyn formulations for treatment of demodex-induced ocular and facial conditions
CA3109543C (en) 2018-09-05 2023-05-23 Zoetis Services Llc Palatable antiparasitic formulations
EP3946325A4 (en) 2019-04-04 2022-12-21 Tarsus Pharmaceuticals, Inc. Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis
EP3986377A4 (en) 2019-06-19 2023-07-19 Tarsus Pharmaceuticals, Inc. ISOXAZOLINE PARASITICIDAL FORMULATIONS AND METHODS OF TREATING BLEPHARITIS
US20220249445A1 (en) 2019-06-19 2022-08-11 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
MX2022000843A (en) 2019-07-22 2022-02-10 Intervet Int Bv SOFT CHEWABLE DOSAGE FORM FOR VETERINARY USE.
BR112022003663A2 (en) 2019-08-28 2022-05-24 Horizon Therapeutics Ireland Dac Method for treating thyroid ophthalmopathy (ted) in an individual with ted; method to reduce proptosis by at least 2 mm in an individual with thyroid ophthalmopathy (ted); method for treating or reducing the severity of diplopia in an individual with thyroid ophthalmopathy (ted); method for treating or reducing the severity of thyroid ophthalmopathy (ted); method for reducing proptosis in an eye in an individual with thyroid ophthalmopathy (ted); method to reduce clinical activity score (cas) of thyroid ophthalmopathy (ted); method for a) reducing proptosis by at least 2 mm and b) reducing the clinical activity score (cas) in an individual with thyroid ophthalmopathy (ted); and method to improve the quality of life in an individual with thyroid ophthalmopathy (ted)
WO2021243014A1 (en) 2020-05-28 2021-12-02 Horizon Therapeutics Ireland Dac Methods for the treatment of idiopathic orbital inflammation and related conditions

Also Published As

Publication number Publication date
US20220054457A2 (en) 2022-02-24
IL307992A (en) 2023-12-01
US11690827B2 (en) 2023-07-04
US20220362218A1 (en) 2022-11-17
KR20250065422A (en) 2025-05-12
BR112020012018A2 (en) 2020-11-24
IL275339B1 (en) 2023-11-01
HUE067461T2 (en) 2024-10-28
US20190183862A1 (en) 2019-06-20
DK3723739T3 (en) 2024-06-17
CN111655241A (en) 2020-09-11
EP3723739A4 (en) 2022-04-20
AU2018385766A1 (en) 2020-07-23
KR20250059552A (en) 2025-05-02
IL275339A (en) 2020-07-30
US20210196689A1 (en) 2021-07-01
US20250312317A1 (en) 2025-10-09
NZ766141A (en) 2024-01-26
US20230190711A1 (en) 2023-06-22
ES2981130T3 (en) 2024-10-07
EP3723739B1 (en) 2024-03-27
EP3723739A1 (en) 2020-10-21
MX2024000828A (en) 2024-02-08
EP4397375A3 (en) 2024-09-25
US20220354829A1 (en) 2022-11-10
US12171750B2 (en) 2024-12-24
US20230301971A1 (en) 2023-09-28
US20210077465A1 (en) 2021-03-18
AU2018385766B2 (en) 2022-12-01
US20250127762A1 (en) 2025-04-24
US20220354830A1 (en) 2022-11-10
US20250312318A1 (en) 2025-10-09
JP2021506971A (en) 2021-02-22
PL3723739T3 (en) 2024-09-16
JP2024038449A (en) 2024-03-19
AU2023200843A1 (en) 2023-03-16
KR20250057155A (en) 2025-04-28
KR20200111177A (en) 2020-09-28
IL307992B1 (en) 2024-11-01
US10835517B2 (en) 2020-11-17
US12213964B2 (en) 2025-02-04
EP4397375A2 (en) 2024-07-10
RU2020122841A (en) 2022-01-18
IL316352A (en) 2024-12-01
US11690826B2 (en) 2023-07-04
US20250017908A1 (en) 2025-01-16
IL275339B2 (en) 2024-03-01
CA3085787A1 (en) 2019-06-20
MX2020006309A (en) 2021-01-29
AU2025204628A1 (en) 2025-07-10
ZA202004155B (en) 2023-01-25
US12364685B2 (en) 2025-07-22
SI3723739T1 (en) 2024-08-30
US20230293496A1 (en) 2023-09-21
US20210077466A1 (en) 2021-03-18
US11752137B2 (en) 2023-09-12
FI3723739T3 (en) 2024-06-19
WO2019118928A1 (en) 2019-06-20
PT3723739T (en) 2024-06-21
CN119174758A (en) 2024-12-24
AU2023200843B2 (en) 2025-04-03
CN111655241B (en) 2024-10-15
US11197847B2 (en) 2021-12-14
CN119157876A (en) 2024-12-20

Similar Documents

Publication Publication Date Title
IL307992B2 (en) Isoxazoline parasiticide formulations and methodsfor treating blepharitis
JP7012075B2 (en) Pharmaceutical composition for use in the treatment of blepharitis
Sandford et al. Therapeutic potential of castor oil in managing blepharitis, meibomian gland dysfunction and dry eye
KR102097663B1 (en) Compositions and treatment for eye diseases and disorders
ES2750123T3 (en) Compositions and methods for non-surgical treatment of ptosis
JP2019532931A5 (en)
US10406203B2 (en) Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents
MX2021016055A (en) FORMULATIONS AND METHODS OF ISOXAZOLINE PARASITICIDES FOR THE TREATMENT OF BLEPHARITIS.
Elewski Safe and effective treatment of seborrheic dermatitis
JP5153948B1 (en) Allergic rhinitis coating agent
US9011943B2 (en) Compositions and methods for alleviating skin disorders
Day et al. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension
DE102010026696A1 (en) Use of a grease pencil for medical application of active ingredients on the edge of the eyelid, for e.g. treating allergic diseases of the eye, changes in intraocular pressure, preferably glaucoma, and inflammations of the eye
Hakim et al. Medical management of blepharitis
US20220133830A1 (en) Topical composition for control of demodex
RU2022100077A (en) ISOXAZOLINE PARASITICIDAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLEPHARITIS
NZ766141B2 (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
US20200093887A1 (en) Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents
CH712627A2 (en) Hair growth promoting composition and application.
HK1210968B (en) Compositions and treatment for eye diseases and disorders